Analyst Ananda Ghosh of H.C. Wainwright maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report), retaining the price target of $80.00.
Ananda Ghosh has given his Buy rating due to a combination of factors that highlight the promising potential of Structure Therapeutics, Inc.’s drug, aleniglipron (GSBR-1290). The drug’s unique structure, combining the best attributes of orforglipron and danuglipron, positions it as potentially best-in-class. Early efficacy data is impressive, showing a 6.9% placebo-adjusted weight loss over 12 weeks, outperforming competitors under similar conditions. Furthermore, the drug’s clean safety profile, particularly regarding liver toxicity, supports its suitability for long-term therapy and higher dosing in trials.
Additionally, the pharmacokinetic profile of the tablet form indicates rapid exposure, which could enhance efficacy over a 36-week trial period. The potential for significant weight loss, possibly reaching 12-15%, is seen as encouraging. The drug’s ability to expand its application to other metabolic diseases, such as Type 2 diabetes and MASH, further underscores its upside potential. The well-designed ACCESS trials, supported by Phase 2 data, reinforce the confidence in achieving competitive weight loss outcomes, making the stock a compelling buy.
According to TipRanks, Ghosh is ranked #7123 out of 9390 analysts.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $87.00 price target.